Txndc12 Antibody

What is TXNDC12 and why is it important in research?

TXNDC12, also known as thioredoxin domain containing 12, is a protein located in the endoplasmic reticulum. It has a calculated molecular weight of approximately 19 kDa and consists of 172 amino acids. TXNDC12 has emerged as an important research target due to its involvement in multiple cancer types and cellular processes. It contains thioredoxin domains that are critical for its function in redox regulation.

The protein has been found to be significantly upregulated in various cancers, including gliomas and pancreatic cancer, where its high expression correlates with poor patient prognosis . Recent research has revealed TXNDC12's role in inhibiting ferroptosis, a form of regulated cell death characterized by lipid peroxidation, making it an attractive target for cancer research .

What experimental applications are TXNDC12 antibodies validated for?

TXNDC12 antibodies have been validated for several experimental applications including:

• Cytometric bead array (CBA): Mouse monoclonal TXNDC12 antibodies have been validated as part of matched antibody pairs for quantitative detection of TXNDC12 in solution .

• Indirect ELISA: The antibodies can effectively detect TXNDC12 in ELISA-based applications .

• Immunohistochemistry (IHC): TXNDC12 antibodies have been used to detect the protein in tissue sections, as demonstrated in studies examining glioma specimens .

• Western Blot: Researchers have successfully employed TXNDC12 antibodies to detect protein expression levels in various cancer cell lines .

• Co-immunoprecipitation (Co-IP): TXNDC12 antibodies have been used to investigate protein-protein interactions, such as the interaction between TXNDC12 and GGT7 .

For optimal results, each application requires specific optimization of antibody concentration and experimental conditions.

What are appropriate positive and negative controls for TXNDC12 antibody experiments?

When conducting experiments with TXNDC12 antibodies, appropriate controls are essential to ensure result validity:

Positive Controls:

• Human cancer cell lines with known high TXNDC12 expression, such as K562 leukemia cells, HCT116, or SW48 colorectal cancer cells, which have been documented to express high levels of TXNDC12 .

• Glioma tissue samples, which show significantly higher TXNDC12 expression compared to normal brain tissue .

• Recombinant TXNDC12 protein can serve as a positive control for antibody specificity testing.

Negative Controls:

• Normal brain tissue has been used as a negative control in glioma studies, showing minimal TXNDC12 expression .

• Cell lines with TXNDC12 knockdown using siRNA (such as si-1: 5'-GCAAAGCUCUAAAGCCCAATT-3' and si-2: 5'-GGAUGAAGAGGAACCCAAATT-3') can serve as experimental negative controls .

• Primary antibody omission control to detect non-specific binding of secondary antibodies.

• Isotype control antibodies (Mouse IgG1) to identify potential non-specific binding.

How should TXNDC12 antibodies be stored and handled for optimal performance?

For optimal performance and longevity of TXNDC12 antibodies, proper storage and handling procedures should be followed:

• Storage temperature: TXNDC12 antibodies should be stored at -80°C for long-term preservation .

• Buffer conditions: The antibody is typically supplied in PBS only (BSA and azide free) at a concentration of 1 mg/mL .

• Aliquoting: To avoid repeated freeze-thaw cycles, which can diminish antibody activity, it is recommended to aliquot the antibody upon receipt.

• Thawing: When needed for experiments, thaw aliquots at room temperature or on ice rather than at higher temperatures.

• Working dilutions: Prepare working dilutions immediately before use and discard any unused diluted antibody.

• Contamination prevention: Use sterile techniques when handling antibodies to prevent microbial contamination.

Following these guidelines will help maintain antibody integrity and ensure consistent experimental results.

How does TXNDC12 expression correlate with cancer progression and patient prognosis?

TXNDC12 expression has emerged as a potential biomarker for cancer progression and patient outcomes. Research findings indicate:

• Gliomas: TXNDC12 is significantly upregulated in glioma tissues compared to normal brain tissue. Its expression increases with tumor grade, with higher expression observed in WHO grade III and IV gliomas compared to lower grades .

• Prognostic value: Patients with high TXNDC12 expression generally have shorter survival times across multiple cancer types. In glioma patients, high TXNDC12 expression is associated with poor prognosis .

• Correlation with molecular markers: TXNDC12 expression correlates with IDH mutation status and 1p19q co-deletion status in gliomas. Its expression increases in IDH-wildtype tumors and 1p19q non-deleted tumors, which are known to have worse outcomes .

• Pancreatic cancer: In pancreatic adenocarcinoma (PAAD), elevated TXNDC12 expression is associated with enhanced tumor cell proliferation, migration, and invasion capabilities .

• Colorectal cancer: Higher baseline expression of TXNDC12 in colorectal cancer cell lines (HCT116 and SW48) correlates with increased resistance to ferroptosis-inducing agents .

These findings suggest that TXNDC12 expression analysis could complement existing molecular markers in cancer diagnosis and prognosis prediction.

What is the role of TXNDC12 in ferroptosis resistance mechanisms?

TXNDC12 has been identified as a key player in ferroptosis resistance, particularly in cancer cells:

• Upregulation during ferroptotic stress: TXNDC12 expression is upregulated in leukemia cells (HL60 and K562) treated with ferroptosis inducers such as erastin or RSL3, suggesting a protective response .

• Lipid peroxidation inhibition: TXNDC12 functions to inhibit lipid peroxidation, a hallmark of ferroptosis. Genetic knockdown of TXNDC12 enhances ferroptosis sensitivity by promoting lipid peroxidation .

• GSH/GGT7 axis regulation: In pancreatic cancer cells, TXNDC12 interacts with GGT7 to maintain glutathione (GSH) homeostasis. Knockdown of TXNDC12 results in decreased intracellular GSH content and increased GSSG (oxidized glutathione) levels, along with elevated markers of ferroptosis such as malondialdehyde (MDA) and reactive oxygen species (ROS) .

• Cancer cell type specificity: The ferroptosis resistance conferred by TXNDC12 appears to be more pronounced in certain cancer cell types. For instance, colorectal cancer cell lines HCT116 and SW48 exhibit higher TXNDC12 expression and greater erastin resistance compared to MCF7, U2OS, and PANC1 cell lines .

• Therapeutic implications: Targeting TXNDC12 enhances the anticancer activity of ferroptosis-mediated tumor suppression in vivo, suggesting a potential therapeutic strategy .

This protective role of TXNDC12 against ferroptosis represents a novel mechanism by which cancer cells may evade this form of cell death.

How can TXNDC12 antibodies be used to investigate the GSH/GGT7 axis in cancer cells?

TXNDC12 antibodies can be instrumental in exploring the relationship between TXNDC12, GGT7, and glutathione metabolism:

Co-immunoprecipitation (Co-IP) studies:

• TXNDC12 antibodies can be used to pull down TXNDC12 and associated proteins, followed by detection of GGT7 to confirm their interaction. The STRING database prediction of TXNDC12-GGT7 interaction was validated using Co-IP assays .

• A standard protocol involves lysing cells in an appropriate buffer, incubating lysates with TXNDC12 antibody, capturing immune complexes with protein A/G beads, and analyzing precipitates by western blotting for GGT7.

Functional studies following manipulation of TXNDC12:

• TXNDC12 knockdown followed by assessment of GSH/GSSG levels: After siRNA-mediated knockdown of TXNDC12, researchers can measure intracellular GSH and GSSG levels using commercially available assay kits .

• Measurement of ferroptosis markers: Following TXNDC12 knockdown, antibodies can be used to detect changes in ferroptosis-related proteins by western blot, complemented by assays for MDA and ROS levels .

Rescue experiments:

• The effect of TXNDC12 knockdown on GSH metabolism and ferroptosis can be assessed with and without GGT7 overexpression to determine if GGT7 can rescue the phenotype .

• Similarly, the addition of exogenous GSH can be tested for its ability to rescue the effects of TXNDC12 knockdown.

Domain-specific functional analysis:

• Antibodies recognizing specific domains of TXNDC12 can help identify which regions are critical for interaction with GGT7 and regulation of GSH metabolism.

• Truncated or mutant versions of TXNDC12 (such as the Cys66/Cys69 to serine mutant) can be expressed and analyzed for their interaction with GGT7 and impact on GSH levels .

These approaches provide a comprehensive toolkit for researchers investigating the mechanistic details of how TXNDC12 regulates ferroptosis through the GSH/GGT7 axis.

What are the technical considerations for using TXNDC12 antibodies in multiplex assays?

When incorporating TXNDC12 antibodies into multiplex assays, researchers should consider several technical aspects to ensure reliable results:

Antibody pair selection:

• For cytometric bead arrays or sandwich ELISA assays, validated antibody pairs should be used. For example, mouse monoclonal TXNDC12 antibody pairs such as 60622-1-PBS (capture) and 60622-2-PBS (detection) or 60622-1-PBS (capture) and 60622-3-PBS (detection) have been validated for cytometric bead array applications .

• Ensure that the epitopes recognized by each antibody in the pair do not overlap to avoid competition for binding.

Conjugation considerations:

• Use conjugation-ready formats (BSA and azide-free) for direct labeling with fluorophores, biotin, or other detection molecules .

• Optimize the conjugation protocol to maintain antibody affinity and specificity.

• Validate conjugated antibodies to ensure that conjugation has not altered binding characteristics.

Cross-reactivity testing:

• Thoroughly test for cross-reactivity with other proteins in the multiplex panel.

• Include appropriate controls to detect any non-specific interactions.

• Consider using absorption controls where antibodies are pre-incubated with recombinant TXNDC12 to confirm specificity.

Signal optimization:

• Titrate antibody concentrations to determine optimal working dilutions for multiplex formats.

• Evaluate potential matrix effects when detecting TXNDC12 in complex samples.

• Establish standard curves using recombinant TXNDC12 protein to ensure quantitative accuracy.

Data analysis considerations:

• Apply appropriate statistical methods to analyze multiplex data.

• Account for potential signal spillover between detection channels.

• Implement normalization strategies if comparing TXNDC12 levels across multiple samples or experimental conditions.

By addressing these considerations, researchers can successfully integrate TXNDC12 antibodies into multiplex experimental platforms for more comprehensive and efficient analyses.

How can researchers differentiate between TXNDC12 and other members of the thioredoxin family?

Differentiating TXNDC12 from other thioredoxin family proteins requires careful antibody selection and experimental design:

Antibody specificity:

• Select antibodies that target unique epitopes of TXNDC12 not shared with other family members, particularly TXNDC5, which has been extensively studied in various diseases .

• Validate antibody specificity using recombinant proteins and/or knockout/knockdown systems.

• Consider using monoclonal antibodies that recognize specific regions of TXNDC12 not conserved in other thioredoxin domain-containing proteins.

Western blot differentiation:

• TXNDC12 has a distinct molecular weight (19 kDa) that differs from other thioredoxin family members, allowing differentiation by size on western blots.

• Use positive controls with known expression of specific thioredoxin family members alongside experimental samples.

• Consider running parallel blots with antibodies against multiple thioredoxin family proteins for comparative analysis.

Genetic approaches:

• Use specific siRNA or shRNA sequences targeting TXNDC12 (such as si-1: 5'-GCAAAGCUCUAAAGCCCAATT-3' and si-2: 5'-GGAUGAAGAGGAACCCAAATT-3') to confirm antibody specificity by demonstrating reduced signal following knockdown.

• CRISPR-Cas9 gene editing can be employed to create TXNDC12 knockout cell lines as negative controls.

qRT-PCR complementation:

• Complement protein detection with qRT-PCR using primers specific to TXNDC12 (such as 5-GTCCTGCTGATTGTGAAAATGGC-3 and 5-TGATCCATGTCGAGGGTCAAA-3) to confirm expression patterns at the mRNA level.

Functional assays:

• Leverage the unique functional properties of TXNDC12, such as its role in ferroptosis resistance and interaction with GGT7, to differentiate it from other thioredoxin family members.

• Perform Co-IP experiments to identify specific binding partners that uniquely interact with TXNDC12.

By employing these strategies, researchers can confidently distinguish TXNDC12 from other related proteins and ensure the specificity of their experimental findings.

What are effective protocols for using TXNDC12 antibodies in immunohistochemistry?

Based on published research, an effective immunohistochemistry protocol for TXNDC12 detection includes:

Sample preparation:

• Use formalin-fixed, paraffin-embedded (FFPE) tissue sections cut to approximately 5 μm thickness .

• Include appropriate positive controls (such as glioma tissue) and negative controls (normal brain tissue) .

Staining protocol:

• Deparaffinize sections with xylene and rehydrate through a graded ethanol series.

• Perform antigen retrieval (typically heat-induced epitope retrieval in citrate buffer pH 6.0).

• Block endogenous peroxidase activity using 3% hydrogen peroxide for 10 minutes at room temperature .

• Block non-specific binding with fetal bovine serum.

• Incubate with primary TXNDC12 antibody (such as A14403, ABclonal) overnight at 4°C .

• Wash sections thoroughly with PBS.

• Incubate with appropriate secondary antibody (e.g., Goat Anti-Rabbit IgG) for 2 hours at room temperature .

• Visualize using a diaminobenzidine (DAB) substrate kit and counterstain with hematoxylin .

• Dehydrate, clear, and mount sections.

Evaluation of staining:

• Brown staining should be considered a positive feature in cells .

• Assess both staining intensity and percentage of positive cells.

• Consider comparing TXNDC12 expression with other markers such as IDH mutation and 1p19q co-deletion status in gliomas .

This protocol has been successfully used to demonstrate increased TXNDC12 expression in high-grade gliomas compared to normal brain tissue.

How can TXNDC12 antibodies be used to study its role in cancer cell resistance to therapy?

TXNDC12 antibodies can be instrumental in investigating how this protein contributes to cancer therapy resistance:

Ferroptosis-based therapy resistance:

• Use TXNDC12 antibodies in western blot analysis to monitor protein expression changes in cancer cells before and after treatment with ferroptosis inducers such as erastin or RSL3 .

• Combine with cell viability assays to correlate TXNDC12 expression levels with resistance to ferroptosis-inducing agents.

• Perform knockdown or overexpression experiments followed by antibody-based detection to establish causality between TXNDC12 levels and therapy resistance.

Experimental approach for combination therapies:

• Treat cancer cell lines with standard chemotherapeutic agents with and without TXNDC12 knockdown.

• Use TXNDC12 antibodies to confirm knockdown efficiency.

• Assess changes in cell viability, proliferation, and apoptosis markers.

• Analyze GSH levels and ferroptosis markers (MDA, ROS) to determine if TXNDC12-mediated protection involves these pathways .

In vivo studies:

• Use TXNDC12 antibodies for immunohistochemical analysis of tumor xenografts treated with various therapeutic agents to assess protein expression patterns.

• Correlate TXNDC12 expression with tumor response or resistance to therapy.

• Implement tissue microarrays of patient samples to evaluate TXNDC12 as a predictive biomarker for therapy response.

Mechanistic investigation:

• Employ Co-IP with TXNDC12 antibodies to identify therapy-induced changes in protein interactions, particularly with GGT7 and other proteins involved in redox regulation .

• Combine with GSH/GSSG ratio assessment to understand how TXNDC12 modulates the cellular redox state during therapy.

These approaches can provide valuable insights into how TXNDC12 contributes to therapy resistance and may identify strategies to overcome such resistance.

What are the key considerations when designing experiments to analyze TXNDC12 in different cancer types?

When investigating TXNDC12 across different cancer types, researchers should consider several key factors:

Cancer-specific expression patterns:

• Different cancer types show varying levels of TXNDC12 expression. For instance, colorectal cancer cell lines HCT116 and SW48 exhibit higher TXNDC12 expression compared to breast cancer (MCF7), osteosarcoma (U2OS), and pancreatic cancer (PANC1) cell lines .

• Design experiments to compare baseline TXNDC12 expression across cancer types using standardized western blot or qRT-PCR protocols.

Correlation with clinical parameters:

• For each cancer type, analyze TXNDC12 expression in relation to specific clinical parameters relevant to that cancer (such as IDH mutation and 1p19q co-deletion in gliomas) .

• Consider using tissue microarrays to efficiently analyze TXNDC12 expression across multiple patient samples.

Cancer-specific functional effects:

• The functional impact of TXNDC12 may vary between cancer types. In pancreatic cancer, TXNDC12 knockdown inhibits proliferation, migration, and invasion and promotes apoptosis , while in other cancers, its primary role may be in ferroptosis resistance .

• Design functional assays relevant to the specific cancer type being studied (e.g., invasion assays for highly metastatic cancers).

Selection of appropriate experimental models:

• Choose cell lines that accurately represent the cancer type of interest.

• Consider patient-derived xenografts or organoids for more clinically relevant models.

• For in vivo studies, select appropriate animal models that recapitulate the cancer type being investigated.

Experimental controls:

• Include normal tissue counterparts specific to each cancer type as controls.

• Use multiple cell lines representing the same cancer type to account for intra-cancer heterogeneity.

Technical standardization:

• Standardize antibody concentrations, incubation times, and detection methods across cancer types for valid comparisons.

• Consider using automated systems for immunohistochemistry to minimize technical variability when comparing multiple cancer types.

By addressing these considerations, researchers can conduct robust comparative analyses of TXNDC12 across different cancer types and potentially identify cancer-specific roles and therapeutic implications.

How can researchers troubleshoot inconsistent results when using TXNDC12 antibodies?

When encountering inconsistent results with TXNDC12 antibodies, researchers can implement the following troubleshooting strategies:

Antibody validation issues:

• Verify antibody specificity using positive and negative controls, particularly cell lines with known high TXNDC12 expression (HCT116, SW48, K562) versus those with lower expression (MCF7, U2OS) .

• Perform TXNDC12 knockdown experiments using validated siRNA sequences (such as 5'-GCAAAGCUCUAAAGCCCAATT-3') to confirm antibody specificity.

• Consider testing multiple TXNDC12 antibodies that recognize different epitopes to confirm results.

Technical variability:

• Standardize protein extraction protocols to ensure consistent TXNDC12 detection, as different lysis buffers may affect antibody recognition.

• Optimize antibody concentration through titration experiments to determine the optimal working dilution for each application.

• Standardize incubation times and temperatures across experiments.

Sample-related issues:

• Ensure proper sample handling to prevent protein degradation, as TXNDC12 is a relatively small protein (19 kDa) that may be susceptible to degradation.

• For clinical samples, account for pre-analytical variables such as fixation time (for IHC) or freeze-thaw cycles (for cell/tissue lysates).

• Consider the impact of cell confluence and growth conditions on TXNDC12 expression levels.

Application-specific optimization:

• For Western blot: Optimize transfer conditions for small proteins, consider using PVDF membranes with smaller pore sizes, and test different blocking reagents to reduce background.

• For IHC: Optimize antigen retrieval methods, test different antibody diluents, and consider signal amplification systems for weak signals.

• For multiplex assays: Test for potential interference between antibodies and optimize antibody pairs for compatible performance.

Data analysis considerations:

• Use appropriate normalization controls for quantitative analyses.

• Apply consistent analysis parameters across experiments.

• Consider technical replicates to assess reproducibility.

By systematically addressing these potential issues, researchers can improve the consistency and reliability of TXNDC12 antibody-based experiments.

What methodological approaches can enhance the detection sensitivity of TXNDC12 in clinical samples?

To enhance TXNDC12 detection sensitivity in clinical samples, researchers can employ several methodological approaches:

Sample preparation optimization:

• For tissue samples, optimize fixation protocols to preserve TXNDC12 epitopes. Brief fixation times with neutral buffered formalin may better preserve protein antigenicity.

• For protein extracts, use optimized lysis buffers containing appropriate protease inhibitors to prevent TXNDC12 degradation.

• Consider using phosphatase inhibitors if studying potential post-translational modifications of TXNDC12.

Signal amplification techniques:

• Implement tyramide signal amplification (TSA) for IHC applications to enhance chromogenic or fluorescent signals.

• Use polymer-based detection systems rather than traditional avidin-biotin methods for improved sensitivity in IHC.

• Consider proximity ligation assay (PLA) for detecting TXNDC12 interactions with other proteins (such as GGT7) with single-molecule sensitivity.

Advanced detection platforms:

• Utilize highly sensitive detection methods such as digital ELISA or Single Molecule Array (Simoa) technology for quantifying TXNDC12 in serum or other biological fluids.

• Consider mass spectrometry-based approaches, particularly selected reaction monitoring (SRM) or parallel reaction monitoring (PRM), for precise quantification of TXNDC12 peptides.

Antibody engineering approaches:

Pre-enrichment strategies:

• Implement immunoprecipitation or other enrichment steps before detection to concentrate TXNDC12 from dilute samples.

• Use laser capture microdissection to isolate specific cell populations from heterogeneous tissue samples before TXNDC12 analysis.

Technical controls for sensitivity assessment:

• Include serial dilutions of recombinant TXNDC12 protein to establish detection limits.

• Use cell lines with known TXNDC12 expression levels as calibrators for clinical sample analysis.

These approaches can significantly improve the sensitivity and reliability of TXNDC12 detection in clinical samples, enabling more accurate assessment of its expression and potential utility as a biomarker.